These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 26680649)
1. New concept: cellular senescence in pathophysiology of cholangiocarcinoma. Sasaki M; Nakanuma Y Expert Rev Gastroenterol Hepatol; 2016; 10(5):625-38. PubMed ID: 26680649 [TBL] [Abstract][Full Text] [Related]
2. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma. Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593 [TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863 [TBL] [Abstract][Full Text] [Related]
5. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis. Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685 [TBL] [Abstract][Full Text] [Related]
6. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease? Mohr R; Özdirik B; Knorr J; Wree A; Demir M; Tacke F; Roderburg C Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679791 [TBL] [Abstract][Full Text] [Related]
7. Polycomb group protein Bmi1 is overexpressed and essential in anchorage-independent colony formation, cell proliferation and repression of cellular senescence in cholangiocarcinoma: tissue and culture studies. Sasaki M; Yamaguchi J; Ikeda H; Itatsu K; Nakanuma Y Hum Pathol; 2009 Dec; 40(12):1723-30. PubMed ID: 19695678 [TBL] [Abstract][Full Text] [Related]
11. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma. Wei M; Lü L; Lin P; Chen Z; Quan Z; Tang Z Cancer Lett; 2016 Sep; 379(2):253-61. PubMed ID: 26940139 [TBL] [Abstract][Full Text] [Related]
12. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368 [TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940 [TBL] [Abstract][Full Text] [Related]
14. Comment on: isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Gradilone A; Gazzaniga P; Raimondi C; Aglianò AM; Frati L Int J Cancer; 2011 Apr; 128(8):1997-8. PubMed ID: 20568108 [No Abstract] [Full Text] [Related]
15. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. Nakanuma Y; Harada K; Ishikawa A; Zen Y; Sasaki M J Hepatobiliary Pancreat Surg; 2003; 10(4):265-81. PubMed ID: 14598145 [TBL] [Abstract][Full Text] [Related]
17. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855 [TBL] [Abstract][Full Text] [Related]